首页 | 本学科首页   官方微博 | 高级检索  
     


Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin,Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer
Authors:Joachim von Pawel  David R. Spigel  Thomas Ervin  György Losonczy  Fabrice Barlesi  Erzsébet Juhász  Maria Anderson  Bruce McCall  Eric Wakshull  Priti Hegde  Weilan Ye  Daniel Chen  Ilsung Chang  Ina Rhee  Martin Reck
Affiliation:1. Asklepios Fachkliniken GmbH, Gauting, Germany;2. Tennessee Oncology, Nashville, Tennessee, USA;3. Florida Cancer Specialists, Tampa, Florida, USA;4. Semmelweis Egyetem, Budapest, Hungary;5. Aix Marseille University, Marseille, France;6. Assistance Publique H?pitaux de Marseille, Marseille, France;7. H?pital Nord, Oncologie Multidisciplinaire et Innovations Thérapeutiques dpt, Marseille, France;8. Országos Korányi TBC és Pulmonológiai Intézet, Budapest, Hungary;9. Genentech, Inc., South San Francisco, California, USA;10. LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany
Abstract:
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号